A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population

Fundamental and Clinical Pharmacology

Volumn 26, Issue 3, 2012, Pages 438-443

  Alshatwi, Ali A ^a   Hasan, Tarique N ^a   Shafi, Gowhar ^a   Alsaif, Mohammed A ^b   Al Hazzani, Amal A ^a   Alsaif, Adulaziz A ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Breast cancer; MDM2; Single nucleotide polymorphism; TP53

Indexed keywords

ADULT; ARAB; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MDM2 GENE; NUTRITION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; ARABS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860253710     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00939.x     Document Type: Article

References (32)

1. Bin Amer S.M., Maqbool Z., Nirmal M.S. et al. Gene expression profiling in women with breast cancer in Saudi population. Saudi Med. J. (2008) 29 507-513.
2. Elkum N., Dermime S., Tulbah A., Ajarim D., Almalik O., Al-Tweigeri T. Age 40 and younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience. BMC Cancer (2007) 7 222. doi:.
3. Schmidt Mk., Tommiska J., Broeks A. et al. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. (2009) 11 73-113.
4. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. (2003) 33 357-365.
5. Bond G.L., Hu W., Bond E.E. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 119 591-602.
6. Idbaih A., Boisselier B., Marie Y. et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. (2008) 1198 16-20.
7. Cox D.G., Deer D., Guo Q. et al. The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health study. Cancer Causes Control (2007) 18 621-625.
8. Schmidt M.K., Reincke S., Broeks A. et al. Do MDM2 SNP309 and TP53R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. (2007) 67 9584-9590.
9. Campbell I.G., Eccles D.M., Choon D.Y.H. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. (2006) 240 195-197.
10. Alhopuro P., Ylisaukko-oja S.K., Koskinen W.J. et al. The MDM2 promoter polymorphism SNP309T-G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet. (2005) 42 694-698.
11. Bougeard G., Baert-Desurmont S., Tournier I. et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet. (2006) 43 5310-5313.
12. Ruijs M.W.G., Schmidt M.K., Nevanlinna H. et al. The sinlge-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur. J. Hum. Genet. (2007) 15 110-114.
13. Livak K.J. Allelic discrimination using fluorogenic probes and the 59 nuclease assay. Genet. Anal., (1999) 14 143-149.
14. Malkin D., Li F.P., Strong L.C. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 250 1233-1238.
15. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. (1993) 66 83-92.
16. Runnebaum I.B., Tong X.W., Moebus V., Heilmann V., Kieback D.G., Kreienberg R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum. Genet. (1994) 93 620-624.
17. Palmero E.I., Schüler-Faccini L., Caleffi M. et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. (2008) 261 21-25.
18. Donehower L.A., Harvey M., Slagle B.L. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 356 215-221.
19. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. (1999) 19 1092-1100.
20. Alshatwi A.A. Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR) single nucleotide polymorphisms. Food Chem. Toxicol. (2010) 48 1881-1885.
21. Alshatwi A.A., Hasan T.N., Shafi G. et al. Genetic variation in IL-6 and TNF-α genes with risk of breast cancer in a Saudi population-based case-control study. Breast J. (2011) 18 1-2.
22. Hong Y., Miao X., Zhang X. et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. (2005) 65 9582-9587.
23. Xiong X., Wang M., Wang L. et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk. Res. (2009) 33 1454-1458.
24. Zhang X., Miao X., Guo Y. et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. (2006) 27 110-117.
25. Yang M., Guo Y., Zhang X. et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis (2007) 28 1996-2001.
26. Bittenbring J., Parisot F., Wabo A. et al. MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large Bcell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer (2008) 8 116.
27. Gryshchenko I., Hofbauer S., Stoecher M. et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. (2008) 26 2252-2257.
28. Zhuo X.L., Cai L., Xiang Z.L., Zhuo W.L., Wang Y., Zhang X.Y. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch. Med. Res. (2009) 40 299-305.
29. Phang B.H., Linn Y.C., Li H., Sabapathy K. MDM2 SNP309G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur. J. Cancer (2008) 44 760-766.
30. Hu Z., Jin G., Wang L., Chen F., Wang X., Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol. Biomarkers Prev. (2007) 16 2717-2723.
31. Döhner H., Fischer K., Bentz M. et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic Bcell leukemias. Blood (1995) 85 1580-1589.
32. Nayak M.S., Yang J.M., Hait W.N. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. (2007) 67 5831-5839.